Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HPV Vaccines Clear all
Not listed Not applicable Interventional

Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men

NCT00666107
View directory record Official record
Conditions
Anal Cancer, HIV Infections
Interventions
Gardasil
Biological
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

NCT00122681
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Cervarix™, Havrix™-based investigational formulation
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years · Female only
Enrollment
18,729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Fountain Valley, California • San Diego, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jul 22, 2026, 2:00 PM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Not applicable Interventional

Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs

NCT03726151
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Parent Reminders, Multicomponent clinic-system strategies, Combined Condition
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
17,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Canoga Park, California • Pacoima, California • San Fernando, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00121173
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 22, 2026, 2:00 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

NCT02568566
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
9 Years to 11 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

NCT00798265
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions
Gardasil, Survey
Biological · Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 26 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PreTeenVax Evaluation

NCT03186430
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Comprehensive Vaccine Promotion Package
Behavioral
Lead sponsor
Emory University
Other
Eligibility
11 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
6
States / cities
Canton, Georgia • Duluth, Georgia • Lawrenceville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 22, 2026, 2:00 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems

NCT03887793
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
VACs
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Albany, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engaging Clinical Champions to Improve HPV Vaccination

NCT05736718
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Champion Announcement Approach Training, Traditional Announcement Approach Training
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
9 Years to 12 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Adaptation Of An HPV Education Resource To Promote HPV Vaccination

NCT04974619
View directory record Official record
Conditions
HPV Vaccine, HPV
Interventions
Online survey, Focus groups or Individual Interviews, Interviews
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 22, 2026, 2:00 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial

NCT02535845
View directory record Official record
Conditions
Human Papillomavirus Vaccines
Interventions
Project Voice, HPV Informational Video
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
11 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 22, 2026, 2:00 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

NCT05132803
View directory record Official record
Conditions
Recurrent Human Papillomavirus Type 16 Associated Cancer
Interventions
HPV 16 TA-CIN
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Persuasiveness of Pro-inoculation Arguments

NCT05804825
View directory record Official record
Conditions
Vaccination Hesitancy, Human Papillomavirus Vaccination, Vaccine Refusal
Interventions
Argument inoculation messages, Simple forewarning message
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Jul 22, 2026, 2:00 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination

NCT05148559
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
Reminder Sent Via Preferred Method of Communication, Reminder Sent Via Mailed Letter
Behavioral
Lead sponsor
Huong Nguyen, PhD
Other
Eligibility
12 Years to 12 Years
Enrollment
5,451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Communication Strategies to Increase HPV Vaccination Intention

NCT06784960
View directory record Official record
Conditions
Papilloma Viral Infection, Vaccine Hesitancy, Communication
Interventions
Messages
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
5,337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Not applicable Interventional

HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3

NCT02558803
View directory record Official record
Conditions
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer, Genital Warts, Oropharyngeal Cancer
Interventions
Simple Reminder
Behavioral
Lead sponsor
Regenstrief Institute, Inc.
Other
Eligibility
11 Years to 17 Years
Enrollment
1,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preparedness Study - HPV Vaccine

NCT01489527
View directory record Official record
Conditions
Sexual Transmission of Infection
Interventions
Gardasil Vaccine, Placebo
Biological · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Jul 22, 2026, 2:00 PM EDT
Recruiting Phase 2 Interventional

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

NCT06157151
View directory record Official record
Conditions
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
Interventions
PRGN-2009 plus Pembrolizumab
Biological
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Little Rock, Arkansas • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Active, not recruiting Not applicable Interventional

Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

NCT04469569
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
HPV-PROTECT
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years and older
Enrollment
5,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

NCT00710593
View directory record Official record
Conditions
HIV Infection
Interventions
HPV vaccine for strains -6, -11, -16, and -18
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 23 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Early Phase 1 Interventional

Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine

NCT02546752
View directory record Official record
Conditions
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer
Interventions
THEO
Other
Lead sponsor
Regenstrief Institute, Inc.
Other
Eligibility
11 Years to 17 Years
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Jul 22, 2026, 2:00 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 2:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

NCT04287868
View directory record Official record
Conditions
Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
Interventions
PDS0101, M7824, NHS-IL12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 2:00 PM EDT